Imaging Is Key To Product Development In Critical Path Opportunities List
This article was originally published in The Gray Sheet
Executive Summary
Imaging techniques hold "vast potential" to help speed the development of new medical products, FDA says in the latest report on its Critical Path initiative
You may also be interested in...
FDA Project Focuses On Imaging To Improve Stent Design
Research supported by FDA's "critical path" initiative suggests that computed tomography is a useful tool for studying the mechanical dynamics of stents placed in leg arteries, among the more challenging parts of the body for device use
FDA Project Focuses On Imaging To Improve Stent Design
Research supported by FDA's "critical path" initiative suggests that computed tomography is a useful tool for studying the mechanical dynamics of stents placed in leg arteries, among the more challenging parts of the body for device use
McClellan Tapped To Chair Controversial Reagan-Udall Foundation
Former CMS administrator and FDA commissioner Mark McClellan has been tasked by the Bush administration to lead and lend his good name to the Reagan-Udall Foundation, a federally established nonprofit organization that has yet to have bylaws, but has already come under attack for increasing the window for industry influence on FDA